of lifetime direct medical costs for first-ever stroke patients can have implication in public health policy planning and clinical decision making.

RESEARCH ON METHODS – Data Management & Method Techniques

PRM49 COMPARISON OF COMORBIDITY MEASURES TO PREDICT ECONOMIC OUTCOMES IN A LARGE UK PRIMARY CARE DATABASE

Bessou A1, Guedes F1, Abella S1, Toumi M2, Poole C1

*National School For Statistics and Information Analysis (ENSA), BRUZ, France, 1Creativ, Crastal, Paris, France, 2Vox-Marseille University, Marseille, France, 3Astellas Pharma Europe Ltd, Chertsey, UK

OBJECTIVES: Several indices have been developed to adjust for the effects of comorbidity conditions in observational studies. This study aimed to determine which among selected indices provides the optimal covariate in cost analyses assessing resource utilisation between different treatment strategies using a UK primary care database. METHODS: A retrospective analysis of UK patients continuously registered with a single general medical practice between 01/01/2007 and 01/01/2011 was conducted using the Clinical Practice Research Datalink GOLD dataset (CPRD). Three comorbidity indices were compared: the Charlson Comorbidity Index, original version (CCI) and 2008 adaptation (CCI-2008), and the Quality Outcomes Framework (QOF). In addition, we considered a bespoke index based on an unweighted count of diseases included in the Charlson indices. Two resource use outcomes were analysed: 1) the monthly frequency of primary care consultations; and 2) annual count of biological tests reported over the calendar year 2010. The sensitivity of the comorbidity indices were evaluated for three different look-back periods: 24 and 36 months. For each outcome, we fitted mixed linear regression models on correlation with both consultations (R² ≈ 0.11) and tests (R² ≈ 0.16), followed by the CCI (R² = 0.09 and R² = 0.14 for consultations and tests respectively) and then the QOF measure (R² = 0.08 and R² = 0.11 respectively). Unweighted counts of comorbidities showed similar AIC and R² as their weighted counterparts. The same ranking was observed over the three comorbidity look-back periods. CONCLUSIONS: The CCI-2008 performed better than CCI and QOF to predict units of primary care resource utilisation observed in UK general practice. Further analyses will determine whether these findings are confirmed when predicting health resource use costs and reproducible in other health systems with alternative data collection methods such as claims databases.

PMG50 EFFECT OF FINGOLIMOD ON DISEASE PROGRESSIONS, RELAPSE RATE AND BRAIN ATROPHY IN MULTIPLE SCLEROSIS PATIENTS: REVIEW OF LITERATURE AND PHARMACOECONOMIC CONSIDERATIONS

Rosselli D1, Castañeda-Cardona C2, Lasalvia P1, O’Driscoll M1, Karpf E2, Márquez A2, Mejía N1
1Pontificia Universidad Javeriana, Bogotá, Colombia, 2Pontificia Universidad Javeriana, Bogotá, Colombia

OBJECTIVE: Multiple sclerosis (MS) is a degenerative neurologic disease that seriously affects patients’ quality of life. Fingolimod is a sphingosine-1-phosphate modulator that traps lymphocytes in lymph nodes with neuroprotective effects. Our objective was to review the available data regarding its efficacy in disease progression, relapse rate and brain atrophy and link it to possible pharmacoeconomic effects. METHODS: A systematic review of literature was performed in MEDLINE and Scopus. We included primary studies comparing fingolimod to placebo or other drugs in terms of disease progression, relapse rate and brain atrophy and identified as possible pharmacoeconomic effects. Retrospective designs and studies focusing on specific populations were excluded. Data regarding the outcomes of interest were extracted and processed with Review Manager 5.3. Reviews were presented with forest plots, and heterogeneity analysis was performed. We performed a literature review to assess the possible effect of these clinical outcomes in terms of costs and quality adjusted life years (QALY) in the Colombian context. RESULTS: From the 1,344 references originally identified, only 3 had useful information. Two were placebo-controlled and the other one used interferon β1a (IFNβ1a) as control. Information was available for 1.25 mg and 0.5 mg fingolimod dosing. Statistically significant differences in favor of fingolimod were found in annualized relapse rate, brain volume change, percentage of relapse and disease progression-free patients compared to placebo or IFNβ1a. Results EDSS and MSFC scales change were favorable to fingolimod but not statistically significant. Using data from various sources, we estimated that Colombian patients treated with fingolimod for 5 years might avoid a loss of 0.145 QALY and $ 5,029 of direct and indirect costs. CONCLUSIONS: Fingolimod is superior to placebo and IFNβ1a in disease progression, relapse rate and brain atrophy. More studies are warranted, especially comparing fingolimod to other drugs. The estimated pharmacoeconomic effects are promising but must be interpreted with caution.

PRM51 ONCOLOGY LITERATURE BANK FOR CANCERS AND THERAPIES FOR HEOR: CONCEPT AND UTILIZATION OF ONCOlitbank

Gala S1, Shah A1, Ukwuonah M1, Market Access Solutions LLC, Barran, NJ, USA

OBJECTIVES: We created OncoLitBank, to capture data from clinical trials, patient reported outcomes (PRO) studies, and Health Technology Assessments (HTAs) in oncology, gathered from free full text sources and Social Listening media, that can be used to analyse data for the evolving landscape of chemotherapy agents. METHODS: A systematic literature search was conducted on PubMed for chemotherapy compounds by cancer indications that were either FDA approved or National Comprehensive Cancer Network (NCCN) recommended. The search was limited to studies published between 1960 and 2015 in English language. Phase II, III or IV clinical trials with at least 15 cancer patients assessing side effects of interest were included. PRO studies (not limited to RCTs) reporting quality-of-life (QoL) data for these compounds were included. Additionally, information was extracted from product package inserts of molecules within FDA indication. Archives of 27 HTA bodies were searched for qualitative data of these compounds. Final entries were divided into primary and secondary endpoints, safety, QoL and reimbursement decisions were extracted exhaustively from qualifying studies and HTAs. RESULTS: So far, data are available for 15 cancer agents, including 80 agents in 467 studies. The interactive, user-friendly MS-Excel® based tool can be used to study any selected cancer, including conduct meta-analyses, generate summaries and reports of clinical, PRO and HTA data. The registry provides functionality for a user to make desired assessments via multiple variants, such as line of treatment, tumor-stage, molecule, grade of adverse events and so on. CONCLUSIONS: OncoLitBank provides up-to-date data and a robust platform that can be easily used for systematic reviews, to conduct direct and indirect comparisons, to inform health technology assessment and value development plans. Expansion of searches to other literature databases and trial registries and inclusion of economic and epidemiology studies are underway.

PMG52 GENERATING COSTING ALGORITHMS FOR ONCOLOGY DRUGS USING ADMINISTRATIVE DATABASES

Mittmann N1, Seung SJ2, Cheng SY2, Lin N3, Camacho X3, Macalagian L4, DeAngelis C5, Earle C1
1Sunnybrook Research Institute, Toronto, ON, Canada, 2Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, 3Ottawa Cancer Centre, Toronto, ON, Canada, 4Ontario Institute for Cancer Research, Toronto, ON, Canada

OBJECTIVES: To generate costs and costing algorithms for treatment and supportive drugs in oncology using provincial (Ontario) administrative databases. METHODS: A cohort of women diagnosed with breast cancer (BC) (ICD-9 174.x) was identified from the Ontario Cancer Registry (2007-2010). Firstly, the Ontario Drug Benefit Formulary (ODB), New Drug Assessment and Evaluation (NDAE) and the Alberta Drug Reporting (ALR) databases was used in which BC-specific treatments (chemotherapies and hormonal therapies) and supportive drugs were identified. Secondly, unit costs were applied to calculate the overall and per drug costs in each database. Lastly, costing algorithms were generated to conduct the costing analyses. RESULTS: We identified 30,338 women diagnosed with BC. All chemotherapies and hormonal therapies were named as well as anti-nausea, pain (opioid and non-opioid), anti-infectives, and blood products for supportive drugs. Outputs include number of patient cases with at least one treatment or supportive drug being utilized and total costs. Preliminary results for the 20,076 BC cases prescribed a drug in ODB’s totalled $69.5 million in which $37.5 million was treatment-specific. CONCLUSIONS: We have generated personalized and BC-specific treatment drugs in BC and ALR databases will be determined next. These costing algorithms will allow for the calculation of oncology treatment and supportive drugs cost in different cancer cohorts.

PMG53 “BIG DATA” IN ALZHEIMER’S DISEASE RESEARCH: AN ENVIRONMENTAL SCAN

Hong Y1, Pickering MK2, Perfetto EM3, Allocco J4, Utg B5, Yang K5, Lederer H5
1University of Maryland, School of Pharmacy, Baltimore, MD, USA, 2University of Maryland, School of Medicine, Baltimore, MD, USA

OBJECTIVES: Repositories of “big data” have the potential to play a pivotal role in solving the mysterious challenge of Alzheimer’s disease. However, AD data being generated and aggregated into research databases. An environmental scan was conducted to identify worldwide AD-specific databases and types of data being aggregated and used for AD research. METHODS: A Google search was conducted most recently starting in September 2014 to present. For each database, its URL, geographic location, funding source, and type of data collected and/or stored were identified. A categorization scheme was established to classify types of data. Three reviewers independently categorized the databases in 3 categories. RESULTS: A total of 53 AD databases were identified, both within (28/53) and outside the U.S. (21/53). Sources from outside the U.S. include United Kingdom, Australia, Belgium, France, etc. Four databases represent U.S. and non-U.S. collaborations. The National Institutes of Health is the most common funding source (14/53). Clinical data were found to be the most common (30/53), whereas, databases containing AD-specific claims data appear to be lacking. Additional gaps include a comprehensive database linking claims data with patient-level data from AD longitudinal studies, patient registries, electronic medical records, or genetic data. Patient registry databases lack pre-diagnosis and early-life data, as they enroll patients upon diagnosis with AD or mild cognitive impairment. CONCLUSIONS: Various types of data are being aggregated into numerous AD-specific research databases worldwide. However, gaps exist that may limit the utility of these databases in making advances in the AD research. Efforts are needed to explore opportunities to merge and expand these databases to fill these critical gaps.

PMG54 PHARMACOEUTICAL PRODUCTS AND VACCINES DISCUSSED IN SOCIAL MEDIA: WHICH ONES ARE PATIENTS TALKING ABOUT?

Bell NG1, Schifano L1, Rodriguez H2, Pierce C1, Dasgupta N2, Shaikh S1, Powell GE1
1GSK, RTP, NC, USA, 2Fujifilm, Boston, MA, USA, 3GSK, Uxbridge, NC, USA

OBJECTIVES: Social media and communication tools provide a unique opportunity to enhance traditional pharmacovigilance strategies. The objective of this pilot study was to evaluate the breadth of pharmacoeutical products and vaccines most commonly discussed on Facebook and twitter and how these data may inform future research in this area. METHODS: Publically available Facebook and twitter posts